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MaOBJECTIVES This dual-center study sought to demonstrate the utility and safety of intracardiac echocardiography
(ICE) in providing adequate imaging guidance as an alternative to transesophageal echocardiography (TEE) during
Amplatzer Cardiac Plug device implantation.
BACKGROUND Over 90% of intracardiac thrombi in atrial ﬁbrillation originate from the left atrial appendage (LAA).
Patients with contraindications to anticoagulation are potential candidates for LAA percutaneous occlusion. TEE is
typically used to guide implantation.
METHODS ICE-guided percutaneous LAA closure was performed in 121 patients to evaluate the following tasks typically
achieved by TEE: assessment of the LAA dimension for device sizing; guidance of transseptal puncture; veriﬁcation of the
delivery sheath position; conﬁrmation of location and stability of the device before and after release and continuous
monitoring to detect procedural complications. In 51 consecutive patients, we compared the measurements obtained by
ICE and ﬂuoroscopy to choose the size of the device.
RESULTS The device was successfully implanted in 117 patients, yielding a technical success rate of 96.7%. Procedural
success was achieved in 113 cases (93.4%). Four major adverse events (3 cardiac tamponades and 1 in-hospital transient
ischemic attack) occurred. There was signiﬁcant correlation in the measurements for device sizing assessed by angiog-
raphy and ICE (r ¼ 0.94, p < 0.0001).
CONCLUSIONS ICE imaging was able to perform the tasks typically provided by TEE during implantation of the
Amplatzer Cardiac Plug device for LAA occlusion. Therefore, we provide evidence that the use of ICE offered accurate
measurements of LAA dimension in order to select the correct device sizes. (J Am Coll Cardiol Intv 2014;7:1036–44)
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AB BR EV I A T I O N S
AND ACRONYM S
ACP = Amplatzer Cardiac Plug
AF = atrial ﬁbrillation
CS = coronary sinus
ICE = intracardiac
echocardiography
LAA = left atrial appendage
LAAC = LAA Closure
OAC = oral anticoagulant(s)
RA = right atrium
TEE = transesophageal
echocardiography
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1037The efﬁcacy of chronic anticoagulation therapy to
prevent ischemic strokes in AF is well established (6),
and current guidelines recommend an oral anti-
coagulation (OAC) regimen to prevent thromboem-
bolism to all AF patients at risk of stroke (7,8).
Management of warfarin, the most commonly
administered OAC drug, is complicated by a narrow
therapeutic window, the need for frequent moni-
toring, signiﬁcant drug-to-drug interactions, and the
increased risk of bleeding, which limit the use of
warfarin for a substantial portion of these patients.
Despite the introduction of novel OAC drugs, devel-
oped to overcome these disadvantages (9–11),
a considerable number of AF patients do not re-
ceive OAC due to their bleeding risk or other contra-
indications. For these patients, the option of LAA
occlusion by percutaneous implantation of an occlu-
sive device has shown encouraging results as an
alternative to OAC therapy (12,13).SEE PAGE 1045The use of imaging techniques is of great relevance
throughout all phases of the implantation procedure
for LAA occlusion, speciﬁcally helping in the choice of
the size of the device and in reducing the complication
rate, which is still critical in the preliminary experi-
ence (13). The use of general anesthesia, typically
required by TEE, can be avoided by application of
intracardiac echocardiography (ICE). As previously
reported by MacDonald et al. (14), this technique, used
in LAA evaluation and closure for the ﬁrst time by the
investigators without TEE, reduced procedure time
and can be performed safely under local anesthesia.
We present our dual-center experience regarding
the utility and safety of ICE-guided percutaneous
LAA occlusion as an alternative to implantation under
TEE guidance.
METHODS
Between January 1, 2009 and April 30, 2013, all
consecutive patients undergoing LAA transcatheter
occlusion procedure at the Ospedale del Cuore, Fon-
dazione G. Monasterio in Massa, and at the Azienda
Ospedaliera Universitaria of Careggi in Florence were
enrolled in this study. Patients scheduled for percu-
taneous LAA occlusion had a history of nonrheumatic
AF (chronic, paroxysmal, or persistent), a high stroke
risk, and absolute contraindications to OAC. Contra-
indications to OAC that led to LAAC were extremely
different in our population of 121 patients. In 42%
of cases, patients had histories of major bleeding
(47% of these were on OAC), mostly spontaneous
or OAC-related intracranial bleedings. In 26.4%of cases, patients had histories of minor
bleeding (56% of these were on OAC), mostly
gastrointestinal bleedings. Also, in 9.1% of
cases, there were histories of repeated
thromboembolic events on warfarin. For the
remaining cases, there were further con-
traindications to OAC, such as 2 cases of
cerebral aneurysm, hematological disorders,
carcinomas, high HAS-BLED (Hypertension,
Abnormal renal and liver function, Stroke,
Bleeding, Labile INRs, Elderly, Drugs or
alcohol) scores, as well as others.
CHARACTERISTICS OF THE OCCLUSIONDEVICE. All patients underwent TEE examination
from 2 to 5 days before the procedure to exclude the
presence of thrombus in the LAA and to assess the
LAA anatomy, ostium and landing zone diameters,
and length. In all cases, we were able to verify that
the length of the LAA was $10 mm in order to
correctly deploy the device with sufﬁcient space.
Patients were implanted with the Amplatzer Cardiac
Plug (ACP) device or Amplatzer Cardiac Plug II
(Amulet) (St. Jude Medical, Plymouth, Minnesota).
The ACP device is designed for immediate occlu-
sion of the LAA and consists of a distal lobe and a
proximal disk connected by an articulating waist
(Figure 1). It is a self-expanding device made of a
nitinol mesh and 2 patches of polyester sewn into
both the lobe and the disk. The lobe of the device has
6 stabilizing wires that help to anchor the device in
the LAA. The device is available in sizes between 16
and 30 mm (2-mm size increments, lobe size), and the
proximal disk is 4 to 6 mm larger than the lobe. The
lobe has a ﬁxed length of 6.5 mm irrespective of
device size. The ACP device is recommended to be
oversized by about 2 to 3 mm with respect to the
LAA dimensions. The device has a wide positional
adaptability due to the connecting waist, which al-
lows the disk of the system to self-orient from the
lobe and completely occlude the ostium of the LAA.
The Amulet lobe has 12 stabilizing wires for the
16- and 18-mm devices, 16 stabilizing wires for the
20- to 25-mm devices, and 20 stabilizing wires for the
28- and 34-mm devices. Stabilizing wires help to
anchor the device in the LAA. The device is available in
sizes between 16 and 34 mm (2-mm size incre-
ments lobe size, for the 16- to 22-mmdevices and 3-mm
increments, lobe size, for the 22- to 34-mm devices).
The proximal disk is 6 to 7mm larger than the lobe. The
lobe length is 6.5 mm for the 16- to 22-mm devices and
10mm for the 25- to 34-mmdevices. The Amulet device
is recommended to be oversized by about 2 to 3 mm
with respect to the LAA dimensions (Figure 1).
FIGURE 1 APC and Amulet
An image of the Amplatzer Cardiac Plug (ACP), the left atrial appendage occlusion device used in this study, seen together with the Amulet.
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1038INTRACARDIAC ECHOCARDIOGRAPHY. The implanta-
tion procedures were performed under local anes-
thesia and guided by ﬂuoroscopy and ICE monitoring
using the AcuNav catheter (Biosense Webster, Inc.,
Diamond Bar, California). This system is available
in 2 sizes of 8- and 10.5-F shafts. It works with Se-
quoia, Cypress, or Aspen imaging systems, all of
which are manufactured by Siemens Medical Solu-
tions USA, Inc. (Malvern, Pennsylvania), and VIVID i
(GE Healthcare, GE, Fairﬁeld, Connecticut). The fre-
quency of the transducer varies from 5.5 to 10 MHz.
The catheter can be steered in 4 directions (anterior,
posterior, left, and right). It also has color ﬂow and
spectral Doppler capabilities. Once the desired posi-
tion of the catheter tip has been achieved, it can
be set in that position with a lock mechanism, which
is located on the catheter handle.FIGURE 2 View of the LAA From the Right Atrium and CS
(A) The ﬁgure shows the intracardiac echocardiography view of the left
The long axis of the LAA, the circumﬂex artery, the mitral valve, and the
sinus (CS). View of a pectinate muscle.The ICE probe was positioned in the right atrium
(RA) or in the coronary sinus (CS) position (Figures 2A
and 2B). ICE guidance was used in the following ways:
1) to conﬁrm the absence of LAA thrombus; 2) to
identify the LAA landing zone dimension for the de-
vice sizing; 3) to guide the transseptal puncture; 4) to
verify the delivery sheath position; 5) to conﬁrm the
location and stability of the device before and after
release; and 6) to continuously monitor to detect any
procedural complication, such as cardiac tamponade.
In the last 51 consecutive patients enrolled in
Massa Ospedale del Cuore G. Pasquinucci, ICE was
also used to assess the diameter of the LAA by
measuring the transverse diameter 10 mm below the
ostium, called the landing zone of the device. The
same diameter was then measured by angiography
by a different operator.atrium and left atrial appendage (LAA) as seen from the right atrium.
interatrial septum can be seen. (B) The LAA as seen from the coronary
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1039LAA OCCLUSION: TECHNIQUE. Based on these
measurements, the size of the device was chosen
following the manufacturer’s recommended sheath
size. Positioning and deployment of the device was
performed under combined ﬂuoroscopic and ICE
guidance. The ideal lobe for sheath placement was
decided on the basis of ﬂuoroscopic images. The lobe
of the device was placed inside the LAA, reaching
the chosen landing zone while the disk was posi-
tioned in order to seal the LAA ostium and achieve
complete exclusion of the appendage. Appropriate
implantation was conﬁrmed by a lobe positioned
completely inside the LAA, aligned with the LAA
landing zone and with a slight deformation of its
body (tire-shape) (Figures 3A and 3B). The procedure
has been previously described in detail by Berti et al.
(15). Additional indicators for appropriate implanta-
tion included a clear separation between disk and
lobe and a concave shape of the disk visible by ﬂuo-
roscopy. Contrast ﬂuid was injected through the
sheath to conﬁrm the position of the device and the
effective-LAA occlusion. Device stability was veriﬁed
by either ICE or ﬂuoroscopy, as device embolization
has been reported as a possible complication (12,13). In
all patients, the proximal disk was kept on traction for
at least 3 min to allow the device lobe to anchor within
the LAA trabecular anatomy and to verify device
stability (Figures 4A and 4B).
DATA ANALYSIS. The analysis included data col-
lected with respect to patient demographics and
characteristics, procedural data, and complications
that occurred during the implantation and subsequent
hospitalization. Data were analyzed with emphasisFIGURE 3 View of the APC Correctly Implanted Seen by Fluoroscop
The device after it has been completely released, demonstrating the occl
intracardiac echocardiography (ICE) view. APC ¼ Amplatzer Cardiac Plugon procedure-related aspects and acute treatment
results. Speciﬁcally, the following endpoints were
deﬁned: 1) technical success: successful delivery
and deployment of the device; and 2) procedural
success: technical success and the absence of major
adverse events during hospitalization. Major ad-
verse events included death, stroke, embolism,
pericardial or other major bleeding requiring inter-
vention, device embolization, and major vascular
complications.
All statistical analyses were conducted with the
StatView statistical package (version 5.0.1, SAS Insti-
tute, Cary, North Carolina). Continuous variables are
presented by mean  SD (range) and event rates are
expressed as percentages. Differences between LAA
dimensions measured by ICE and ﬂuoroscopy were
evaluated by paired Student t test. Correlation be-
tween continuous variables was assessed by means of
Pearson correlation coefﬁcient. Statistical signiﬁ-
cance was deﬁned as p < 0.05 (Figure 5).
RESULTS
A total of 121 patients with a history of non-
rheumatic AF of at least 12 months, CHA2DS2VASc
(Congestive heart failure [or left ventricular systolic
dysfunction], Hypertension: blood pressure consis-
tently >140/90 mm Hg [or treated hypertension
on medication], Age $75 years, Diabetes mellitus,
previous Stroke or TIA or thromboembolism, Vas-
cular disease [e.g., peripheral artery disease, myo-
cardial infarction, aortic plaque], Age 65 to 74 years,
Sex category [e.g., female sex]) score $2 and abso-
lute or relative contraindications to OAC werey and ICE
usion of the left atrial appendage from (A) a ﬂuoroscopy view and (B)
.
FIGURE 4 Traction Test Seen by Fluoroscopy and ICE
(A) Fluoroscopy view of the Amplatzer Cardiac Plug traction or stability test LAO 40/CRAN 20. (B) The same test as seen by intracardiac
echocardiography (ICE) and from the coronary sinus. CRAN ¼ cranial; LAO ¼ left anterior oblique.
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1040included. Mean age was 77  7.6 years old (range
56 to 93 years) and 69 patients (57%) were men
(Table 1).
The device was successfully implanted in 117
patients, yielding a technical success rate of 96.7%.
LAA access was achieved by transseptal puncture in
118 of 121 (97.5%) of the cases, and in the remaining
3 cases (2.5%), a patent foramen ovale was used to
enter the LAA.
In 51 patients, we compared the LAA ostium and
landing zone diameters obtained by ICE and5 Regression Plot
howing the signiﬁcant correlation between the angiographic
and intracardiac echocardiography (ICE) measurements of the
zones (LZ).angiography. LAA dimensions measured by ICE and
angiography differed minimally in all patients. The
mean LAA landing zone for device diameter assessed
by ﬂuoroscopy was 21.0  3.5 mm (range 14.0 to 29.4
mm), whereas by ICE it was 20.6  3.3 mm (range 13.6
to 29.0 mm). The landing zones assessed by an-
giography and ICE were signiﬁcantly correlated
(Pearson correlation coefﬁcient r ¼ 0.94, 2-tailed test
p < 0.0001).
Furthermore, ostium and landing zone measure-
ments by ICE were signiﬁcantly related to TEE
(Pearson correlation coefﬁcient r ¼ 0.94, p < 0.0001;TABLE 1 Baseline Characteristics
Patients 121
Male 69 (57)
Age 77  7.6 (56–93)
HAS-BLED score 3.3  1.0
CHA2DS2-VASc score 4.4  1.3
CHF 16 (13.2)
Hypertension 108 (89.3)
Diabetes mellitus 29 (24)
Previous stroke/TIA 38 (31.4)
AF pattern
Permanent 88 (72.7)
Paroxysmal 25 (20.7)
Unknown 8 (6.6)
Values are n, n (%), mean  SD (range), or mean  SD.
AF ¼ atrial ﬁbrillation; CHA2DS2VASc score ¼ Congestive heart failure (or left
ventricular systolic dysfunction), Hypertension: blood pressure consistently
>140/90 mm Hg (or treated hypertension on medication), Age $75 years, Dia-
betes mellitus, previous Stroke or TIA or thromboembolism, Vascular disease
(e.g., peripheral artery disease, myocardial infarction, aortic plaque), Age 65 to
74 years, Sex category (e.g., female sex); CHF ¼ congestive heart failure; HAS-
BLED ¼ Hypertension, Abnormal renal and liver function, Stroke, Bleeding,
Labile INRs, Elderly, Drugs or alcohol; TIA ¼ transient ischemic attack.
FIGURE 6 LAA Measurements
The ostium (yellow line) and landing zone (red line) from pre-procedural transesophageal echocardiography (A) and periprocedural ICE (B) in the same patient. LA¼ left
atrium; MV ¼ mitral valve; other abbreviations as in Figures 1 and 3.
TABLE 2 Complications
Major complications
Serious pericardial effusion* 3 (2.5)
Device embolization 0 (0)
Major bleeding† 0 (0)
Procedure-related ischemic stroke‡ 1 (0.8)
Hemorrhagic stroke 0 (0)
Minor complications
Pericardial effusion, without tamponade 0 (0)
Femoral hematoma§ 2 (1.6)
Others 0 (0)
Values are n (%). *Deﬁned as the need of percutaneous or surgical drainage.
†Deﬁned as a bleeding event that required $2 units of packed red blood cells or
surgery to correct. ‡Transient ischemic attack 24 h after procedure. §One left
femoral hematoma and 1 right femoral hematoma.
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1041r ¼ 0.72, p < 0.0001; for ostium and landing zone,
respectively). More speciﬁcally, in 78.4% of the cases,
the device selected based on ICE measurements
was the same as the device selected based on TEE
measurements. In 21.6% of cases, the device was
1 size larger, and in no cases was it smaller (Figure 6).
Of all 121 patients evaluated by TEE, the majority
(67.7%) had a dual-lobe LAA anatomy that originated
distally 10 mm from the ostium; a single-lobe anatomy
was observed in 17.2% of the patients. The mean
diameter of the device implanted was 24.0  3.5 mm
(range 16 to 34 mm). In 89.7% (105 of 117) of pro-
cedures, the ﬁrst selected device was implanted; in
4 cases, the initial device was replaced by a smaller
device; and in 8 other cases, a larger device was used.
In all procedures, appropriate device positioning
and effective LAA occlusion were accomplished in a
single attempt. No obvious relationship was noticed
between the number of attempts required and the LAA
oriﬁce diameter or the number of LAA lobes. The use of
ICE together with angiography has, in all cases, pro-
vided us with an adequate guide, and in no cases did
we need to refer back to the images acquired with TEE.
ADVERSE EVENTS. Among the 121 procedures, 4
adverse events and 3 minor complications occurred
(Table 2). We had 4 cases of technical failure (3.3% of
total). In 3 cases, the anatomy of the LAA was
characterized by too many lobes and was not suitable
for a device apposition. This was only discovered
by angiography images, because they were notcorrectly detected by pre-procedural TEE. The cause
of the last technical failure was an insufﬁciently sized
landing zone. The most frequent adverse event was
cardiac tamponade, which occurred in 3 patients. Two
cardiac tamponades occurred 4 and 8 h, respectively,
after intervention in patients whose procedures were
prolonged due to many device-retrieval attempts;
both complications were resolved by pericardiocent-
esis. The third cardiac tamponade occurred due to a
LAA perforation and a consequent pulmonary artery
laceration that was resolved surgically (16). In all
these cases we had good ICE-derived images.
No cases of pericardial effusion without tampo-
nade were observed in our cohort.
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1042Another patient experienced a transient ischemic
attack 24 h after the procedure. The brain computed
tomography scan was negative for ischemic lesion,
and the event spontaneously resolved within a few
hours. The patient was discharged without any
sequela. Minor complications included 2 cases of
femoral hematomas. In 1 case, the femoral hematoma
was on left side, the ICE access side. This complica-
tion did not require a blood transfusion or reinter-
vention, only a compression of a major duration
without a prolonged hospitalization.
Accounting for the 4 major adverse events, the
procedural success rate was 93.4% (113 of 121 cases).
DISCUSSION
The use of procedural echocardiography is an essen-
tial requirement for safe and successful percutaneous
LAA occlusion. Without disputing the value of a pre-
procedural TEE examination to explore the relevant
cardiac anatomy and exclude thrombi, our results
suggest that ICE is an acceptable alternative to TEE
during implantation of the ACP device.
ICE is an imaging technique applied in various
interventional cardiac procedures, including catheter
ablation of AF, percutaneous closure of atrial and
ventricular septal defects, and mitral valvuloplasty
(17,18). For a series of 10 patients, ICE imaging during
percutaneous LAA occlusion was previously reported
to be optimal with the ICE probe positioned in the
coronary sinus (19). In 28 of 51 cases, we integrated
the images with views both from the CS and the RA.
While the ICE views from the CS provided good
images, in our experience, this is not fundamental
because we achieved satisfactory images for all pro-
cedural aspects from the standard RA position. Al-
though ICE may result in an inferior image quality
compared with that of TEE, in our experience this is
not affecting the safety and technical success of the
implantation procedure, provided that key informa-
tion is recorded during the pre-procedural TEE
examination. In the case of both pre-procedural
TEE and periprocedural ICE, it is fundamental to
ﬁnd the measures of the LAA ostium and landing
zone. It is not easy to evaluate the full length of
the appendage because of the complex geometry of
the LAA; however, a critical point is to verify that
the minimum length from the neck must be $10 mm
in order to have sufﬁcient room for the correct
deployment of the device.
ICE-guided percutaneous LAA occlusion is
feasible with similar results to those reported for
TEE-guided implantation. Technical success rates
for percutaneous LAA occlusion are reported to be90% and higher (13,20) compared with 96.7% in this
study. Typical rates for major complications,
including signiﬁcant pericardial effusion, tamponade
and periprocedural stroke, are reported to be be-
tween 3.7% and 7.7% (13,20). In this study, adverse
events occurred in 3.4% of the procedures, including
3 pericardial tamponades and 1 transient ischemic
attack. Another critical point is the presence of
peridevice leaks after device implantation. Angiog-
raphy and TEE are undoubtedly more precise than
ICE in monitoring the presence of any peridevice
leaks. In our experience, it has been established that
small leaks that were visible only by angiography
did not present a need for device substitution.
However, leaks that were visible both with angiog-
raphy and ICE were motivation for device
substitution.
As stated by some investigators, there is some
experience of ﬂuoroscopy-only-guided LAAC that
has demonstrated the reliability of a procedure us-
ing local anesthesia and ﬂuoroscopy alone (21). In
our opinion, purely ﬂuoroscopic guidance in LAAC
has signiﬁcant limitations. Hence, complications
may result from suboptimal catheter handling and
device performance from undetected thrombus for-
mation, bleeding, and wall disruption. Especially
for learning curve centers, we recommend the use
of ﬂuoroscopy integrated with echocardiographic
imaging.
Concerning the periprocedural assessment of
the appropriate device size, a high level of agree-
ment was found between results from ﬂuoros-
copy and ICE. The initially selected device was
only exchanged for a differently sized device in 10.3%
of the cases. This compares well with results reported
for the same device by operators using TEE (13,22).
Application of TEE and endotracheal intubation
may contribute to complications such as injuries
and bleeding of gastroesophageal and respiratory
tract, laryngospasm and bronchospasm requiring ad-
ditional intervention, and/or prolonged hospitaliza-
tion. The use of ICE eliminates the need for general
anesthesia, which is beneﬁcial for all, especially
older patients. Moreover, as shown in our study,
left femoral vein hematoma is the only ICE-related
complication, a minor complication not requiring
any blood transfusion reintervention or prolonged
hospitalization. With regard to the percutaneous clo-
sure of interatrial communications, ICE, compared
with TEE, has been reported to result in less proce-
dural discomfort for the patient and reduced proce-
dural time and ionizing radiation exposure (23) and
to avoid the obstruction of ﬂuoroscopic viewing.
Although not assessed in our study, it seems
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1043reasonable to assume that similar beneﬁts exist for
percutaneous LAA occlusion.
The use of ICE instead of TEE does not require
the presence of an anesthesiologist, and therefore
the amount of global exposure to ionizing radia-
tion is also reduced for the operators involved. In
periprocedural use of TEE or ICE, 2 operators are
always necessary (1 for the implantation and 1
for the imaging). The safety issue is the proximity
of the TEE operator to the x-ray tube and the lack of
x-ray screen protection in that position. In peri-
procedural ICE use, both operators are on the
same side as the patient behind the x-ray screen
protection.
It is questionable whether the additional ICE
probe increases the overall cost of the procedure.
That cost is probably balanced by the added cost of
the TEE-experienced echocardiographer, the anes-
thesiology team, and the longer catheterization lab
occupancy. Furthermore, the use of local anesthesia
may reduce direct medication and personnel costs
(24,25), as well secondary costs related to TEE
complications.
In our patients, the visualization of the LAA was
feasible with the ICE using the RA and CS positions,
and the measurements obtained by angiography and
ICE were signiﬁcantly correlated.
The LAA dimension is essential for selecting the
correct size of the device, and we observed that
the accuracy of ICE is comparable with angiography
in evaluating LAA measurements. ICE may represent
a valid support for imaging guidance during the
percutaneous LAA closure procedure.STUDY LIMITATIONS. Our study was a dual-center
observational study without a control group, and
our results may not be extrapolated to other LAA
occlusion devices and other types of ICE catheters.
Further investigations are required to fully charac-
terize the application of ICE during percutaneous LAA
occlusion, including its impact on safety, the length
of learning curve, procedural success, and healthcare
costs.
CONCLUSIONS
Although accepted as the guiding tool for percuta-
neous LAAC device closure procedures and for
electrophysiological catheter-based ablations, ran-
domized multicenter trials on ICE in this context
are lacking. In our experience, ICE represents a safe
and useful ultrasound option for guiding the LAA
transcatheter occlusion procedure and for prevent-
ing short- and mid-term complications having the
advantage over TEE of not requiring the support of
general anesthesia and anesthesiology. These fac-
tors provide direct beneﬁts to patients. Compared
with ﬂuoroscopy, ICE also showed a good accuracy
in assessing LAA dimension in order to select the
correct device sizes.
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